Customs Today
  • Home
  • Islamabad
  • Karachi
  • Lahore
  • National
  • Transfers and Postings
  • Chambers & Associations
  • Business
No Result
View All Result
Customs Today
  • Home
  • Islamabad
  • Karachi
  • Lahore
  • National
  • Transfers and Postings
  • Chambers & Associations
  • Business
No Result
View All Result
Customs Today
No Result
View All Result
Home Breaking News

Russian firm to invest $80m in Pakistan for insulin manufacturing

byCT Report
31/03/2026
in Breaking News, Business, Latest News
Share on FacebookShare on Twitter

ISLAMABAD: A Russian pharmaceutical company has committed to invest around $80 million in Pakistan’s pharmaceutical sector over six years, with plans to establish local insulin manufacturing facilities under regulatory conditions set by the Drug Regulatory Authority of Pakistan, Business Recorder reported.

The regulator has approved maximum retail prices for six insulin products of M/s Genetics Pharmaceuticals and M/s Zavod Medsintez LLC, subject to the condition that the company begins work on local manufacturing and completes it by December 2031.

You might also like

SMEDA announces Rs5m matching grants for SMEs

17/11/2026

Online customs valuation hearings to begin at Lahore: FBR Chairman

17/11/2026

Under the plan, the investment will be carried out in two phases. The first phase involves setting up an aseptic filling plant with an estimated cost of $20 million, to be completed by December 2028. This facility will handle bulk imports and filling of insulin products.

The second phase includes the construction of an active pharmaceutical ingredient (API) production plant, with an estimated investment of $60 million. This facility will cover the full production process, from purification to packaging of insulin products, and is scheduled for completion by December 2031.

The regulator has directed the company to submit detailed timelines for each phase and stated that progress will be monitored. Non-compliance with the commitment to establish local manufacturing could result in cancellation of product registration.

The approved products include insulin formulations such as Rosinsulin C 100IU/ml, which will be imported initially and later produced locally once facilities are operational.

Officials said the move aims to support local production of essential medicines and reduce reliance on imports through phased investment and technology transfer.

Related Stories

SMEDA announces Rs5m matching grants for SMEs

byCT Report
17/11/2026

LAHORE: The Small and Medium Enterprises Development Authority (SMEDA), under the Ministry of Industries and Production, has invited applications from...

Online customs valuation hearings to begin at Lahore: FBR Chairman

byCT Report
17/11/2026

LAHORE: Federal Board of Revenue (FBR) Chairman Rashid Mahmood Langrial said on Tuesday that a dedicated online hearing room for...

Indus Enforcement seizes smuggled goods worth Rs680m in Kalabagh

byCT Report
17/11/2026

KALA BAGH: Collectorate of Indus Enforcement, customs teams raided a dumping site in Missile Colony, Kala Bagh and seized smuggled...

Karachi Enforcement impounds two tankers carrying Iranian fuel worth Rs50.51m

byCT Report
17/11/2026

KARACHI: Collectorate of Customs Enforcement officers seized two tankers loaded with Iranian petrol and diesel in Karachi. The total value...

Next Post

Senate panel warns arrest of some FBR officials in Rs250m cigarette theft case

  • Terms and Conditions
  • Disclaimer

© 2011 Customs Today -World's first newspaper on customs. Customs Today.

No Result
View All Result
  • Transfers and Postings
  • Latest News
  • Karachi
  • Islamabad
  • Lahore
  • National
  • Chambers & Associations
  • Business
  • About Us

© 2011 Customs Today -World's first newspaper on customs. Customs Today.